Shereese Hickson’s doctor wanted her to try the infusion drug Ocrevus for her multiple sclerosis. Even though Hickson is trained as a medical billing coder, she was shocked to see two doses of the drug priced at $123,019, with her share set at $3,620.
Once viewed as a promising cost-control tool, such insurance faces new competition on benefits menus from more traditional insurance. But, according to new research, none of those choices is getting less expensive.
The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.” Officials in California, aware of the state’s bad experience with such plans, are eager to avert their return.
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Hospitals and private investors have pumped vast sums of money into an advanced type of radiology that mostly spares healthy tissue while attacking tumors. The spending hasn’t always paid off — leading some facilities to close or, as in the case of a San Diego center last year, file for bankruptcy.